PTPRS

Across TCGA pan-cancer cohorts, PTPRS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTPRS data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PTPRS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRS expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where PTPRS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.795	1.000	.005	9	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
CCRCC	DFS	Quartile	All	0.950	0.744	.019	4	view →
GBM	DFS	Quartile	All	0.846	0.599	.015	4	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTPRS–LUAD (OS)

Open the LUAD breakdown →